Overview of European Biopharma#
Bernstein has identified the pan-European biopharma sector as a reliable defensive investment. Despite recent changes in market valuations, the sector continues to show steady earnings growth and strong cash generation, which are not fully reflected in current valuations.
Coverage of Major Companies#
Bernstein has started covering several large-cap biopharma companies. Novo Nordisk received an 'Underperform' rating due to potential risks from competition in the U.S. obesity drug market, pricing pressures, and shrinking profit margins. In contrast, Sanofi was rated 'Outperform' based on expectations for stronger growth and value creation driven by management. Novartis and Merck KGaA were rated 'Market Perform' due to limited upside and anticipated earnings challenges.
Top Picks and Specialty Pharma#
Among large-cap companies, Bernstein named AstraZeneca and GSK as top picks, citing their potential for earnings upgrades and sustained growth. In the specialty pharma sector, argenx was highlighted as a top choice, supported by several upcoming catalysts, while Genmab was rated 'Underperform' because it needs acquisitions to counteract impending patent expirations.
Future Growth and Cash Generation#
Bernstein forecasts an annual earnings per share (EPS) growth of about 8% for the biopharma sector from 2025 to 2030. This growth is expected to be driven by stable revenue, careful cost management, and reduced debt levels. The sector is projected to generate approximately $700 billion in cash from 2026 to 2031, which will help companies invest in research, pursue acquisitions, and maintain dividend growth that keeps pace with inflation.
Market Position and Innovations#
Currently, the biopharma sector is trading similarly to the broader European market, even though it has historically been valued higher. Bernstein points to effective pipeline management, improving attitudes towards U.S. drug pricing, and slower global growth as potential factors for a positive re-rating. Additionally, the firm believes that advancements in artificial intelligence could enhance drug development and patient diagnosis, although significant financial benefits may take a decade to materialize.